nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Muscle strain—Metformin—polycystic ovary syndrome	0.0727	0.105	CcSEcCtD
Naltrexone—White blood cell count increased—Metformin—polycystic ovary syndrome	0.0454	0.0658	CcSEcCtD
Naltrexone—Seasonal allergy—Metformin—polycystic ovary syndrome	0.0435	0.063	CcSEcCtD
Naltrexone—Rhinitis seasonal—Metformin—polycystic ovary syndrome	0.0418	0.0605	CcSEcCtD
Naltrexone—Angina unstable—Metformin—polycystic ovary syndrome	0.0361	0.0523	CcSEcCtD
Naltrexone—Sinus headache—Metformin—polycystic ovary syndrome	0.028	0.0405	CcSEcCtD
Naltrexone—Gastrointestinal tract irritation—Metformin—polycystic ovary syndrome	0.0255	0.037	CcSEcCtD
Naltrexone—Tooth abscess—Metformin—polycystic ovary syndrome	0.0218	0.0316	CcSEcCtD
Naltrexone—Appetite absent—Metformin—polycystic ovary syndrome	0.0183	0.0265	CcSEcCtD
Naltrexone—Sinus congestion—Metformin—polycystic ovary syndrome	0.0183	0.0265	CcSEcCtD
Naltrexone—Loose stools—Metformin—polycystic ovary syndrome	0.0165	0.0239	CcSEcCtD
Naltrexone—Toothache—Metformin—polycystic ovary syndrome	0.015	0.0217	CcSEcCtD
Naltrexone—Upset stomach—Metformin—polycystic ovary syndrome	0.0139	0.0202	CcSEcCtD
Naltrexone—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.0113	0.0163	CcSEcCtD
Naltrexone—Rigors—Metformin—polycystic ovary syndrome	0.0112	0.0162	CcSEcCtD
Naltrexone—Chest discomfort—Metformin—polycystic ovary syndrome	0.0103	0.0149	CcSEcCtD
Naltrexone—Nasal congestion—Metformin—polycystic ovary syndrome	0.00727	0.0105	CcSEcCtD
Naltrexone—Lethargy—Metformin—polycystic ovary syndrome	0.00675	0.00979	CcSEcCtD
Naltrexone—Pain in extremity—Metformin—polycystic ovary syndrome	0.00662	0.00959	CcSEcCtD
Naltrexone—Migraine—Metformin—polycystic ovary syndrome	0.00652	0.00944	CcSEcCtD
Naltrexone—Dehydration—Metformin—polycystic ovary syndrome	0.00616	0.00892	CcSEcCtD
Naltrexone—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00605	0.00876	CcSEcCtD
Naltrexone—Cramp muscle—Metformin—polycystic ovary syndrome	0.00596	0.00863	CcSEcCtD
Naltrexone—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00592	0.00857	CcSEcCtD
Naltrexone—Influenza—Metformin—polycystic ovary syndrome	0.00572	0.00829	CcSEcCtD
Naltrexone—Angina pectoris—Metformin—polycystic ovary syndrome	0.00557	0.00807	CcSEcCtD
Naltrexone—Sweating increased—Metformin—polycystic ovary syndrome	0.00557	0.00807	CcSEcCtD
Naltrexone—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00548	0.00795	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00532	0.0077	CcSEcCtD
Naltrexone—Infestation—Metformin—polycystic ovary syndrome	0.0051	0.00739	CcSEcCtD
Naltrexone—Infestation NOS—Metformin—polycystic ovary syndrome	0.0051	0.00739	CcSEcCtD
Naltrexone—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00482	0.00699	CcSEcCtD
Naltrexone—Hepatitis—Metformin—polycystic ovary syndrome	0.00458	0.00663	CcSEcCtD
Naltrexone—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.0045	0.00652	CcSEcCtD
Naltrexone—Eye disorder—Metformin—polycystic ovary syndrome	0.00428	0.0062	CcSEcCtD
Naltrexone—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00425	0.00616	CcSEcCtD
Naltrexone—Angiopathy—Metformin—polycystic ovary syndrome	0.00415	0.00602	CcSEcCtD
Naltrexone—Immune system disorder—Metformin—polycystic ovary syndrome	0.00414	0.00599	CcSEcCtD
Naltrexone—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00413	0.00598	CcSEcCtD
Naltrexone—Chills—Metformin—polycystic ovary syndrome	0.00411	0.00595	CcSEcCtD
Naltrexone—Malnutrition—Metformin—polycystic ovary syndrome	0.00399	0.00577	CcSEcCtD
Naltrexone—Flatulence—Metformin—polycystic ovary syndrome	0.00393	0.00569	CcSEcCtD
Naltrexone—Dysgeusia—Metformin—polycystic ovary syndrome	0.0039	0.00565	CcSEcCtD
Naltrexone—Muscle spasms—Metformin—polycystic ovary syndrome	0.00383	0.00555	CcSEcCtD
Naltrexone—Vision blurred—Metformin—polycystic ovary syndrome	0.00376	0.00544	CcSEcCtD
Naltrexone—Tremor—Metformin—polycystic ovary syndrome	0.00373	0.00541	CcSEcCtD
Naltrexone—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.0037	0.00536	CcSEcCtD
Naltrexone—Malaise—Metformin—polycystic ovary syndrome	0.00359	0.00521	CcSEcCtD
Naltrexone—Syncope—Metformin—polycystic ovary syndrome	0.00357	0.00518	CcSEcCtD
Naltrexone—Palpitations—Metformin—polycystic ovary syndrome	0.00352	0.0051	CcSEcCtD
Naltrexone—Loss of consciousness—Metformin—polycystic ovary syndrome	0.0035	0.00508	CcSEcCtD
Naltrexone—Hypertension—Metformin—polycystic ovary syndrome	0.00344	0.00499	CcSEcCtD
Naltrexone—Chest pain—Metformin—polycystic ovary syndrome	0.00339	0.00492	CcSEcCtD
Naltrexone—Myalgia—Metformin—polycystic ovary syndrome	0.00339	0.00492	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00337	0.00488	CcSEcCtD
Naltrexone—Discomfort—Metformin—polycystic ovary syndrome	0.00335	0.00486	CcSEcCtD
Naltrexone—Oedema—Metformin—polycystic ovary syndrome	0.00325	0.00471	CcSEcCtD
Naltrexone—Infection—Metformin—polycystic ovary syndrome	0.00323	0.00468	CcSEcCtD
Naltrexone—Shock—Metformin—polycystic ovary syndrome	0.0032	0.00464	CcSEcCtD
Naltrexone—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00319	0.00462	CcSEcCtD
Naltrexone—Skin disorder—Metformin—polycystic ovary syndrome	0.00316	0.00458	CcSEcCtD
Naltrexone—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00315	0.00456	CcSEcCtD
Naltrexone—Anorexia—Metformin—polycystic ovary syndrome	0.0031	0.00449	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00296	0.00429	CcSEcCtD
Naltrexone—Paraesthesia—Metformin—polycystic ovary syndrome	0.00292	0.00423	CcSEcCtD
Naltrexone—Dyspnoea—Metformin—polycystic ovary syndrome	0.0029	0.0042	CcSEcCtD
Naltrexone—Somnolence—Metformin—polycystic ovary syndrome	0.00289	0.00419	CcSEcCtD
Naltrexone—Decreased appetite—Metformin—polycystic ovary syndrome	0.00283	0.0041	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00281	0.00407	CcSEcCtD
Naltrexone—Fatigue—Metformin—polycystic ovary syndrome	0.0028	0.00406	CcSEcCtD
Naltrexone—Constipation—Metformin—polycystic ovary syndrome	0.00278	0.00403	CcSEcCtD
Naltrexone—Feeling abnormal—Metformin—polycystic ovary syndrome	0.00268	0.00388	CcSEcCtD
Naltrexone—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00266	0.00385	CcSEcCtD
Naltrexone—Urticaria—Metformin—polycystic ovary syndrome	0.00258	0.00374	CcSEcCtD
Naltrexone—Abdominal pain—Metformin—polycystic ovary syndrome	0.00257	0.00373	CcSEcCtD
Naltrexone—Asthenia—Metformin—polycystic ovary syndrome	0.00233	0.00338	CcSEcCtD
Naltrexone—Pruritus—Metformin—polycystic ovary syndrome	0.0023	0.00333	CcSEcCtD
Naltrexone—Diarrhoea—Metformin—polycystic ovary syndrome	0.00223	0.00322	CcSEcCtD
Naltrexone—Dizziness—Metformin—polycystic ovary syndrome	0.00215	0.00312	CcSEcCtD
Naltrexone—Vomiting—Metformin—polycystic ovary syndrome	0.00207	0.003	CcSEcCtD
Naltrexone—Rash—Metformin—polycystic ovary syndrome	0.00205	0.00297	CcSEcCtD
Naltrexone—Dermatitis—Metformin—polycystic ovary syndrome	0.00205	0.00297	CcSEcCtD
Naltrexone—Headache—Metformin—polycystic ovary syndrome	0.00204	0.00295	CcSEcCtD
Naltrexone—Nausea—Metformin—polycystic ovary syndrome	0.00193	0.0028	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.000306	0.000989	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000306	0.000989	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000306	0.000989	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000301	0.000971	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.0003	0.00097	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000297	0.000959	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000295	0.000953	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000293	0.000947	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000288	0.000931	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000288	0.00093	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PNPLA2—polycystic ovary syndrome	0.000287	0.000928	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—polycystic ovary syndrome	0.000287	0.000926	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000286	0.000925	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000282	0.000912	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000281	0.000906	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00028	0.000906	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000279	0.000901	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000278	0.000898	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000275	0.00089	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000275	0.000887	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AR—polycystic ovary syndrome	0.000275	0.000887	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000274	0.000884	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000273	0.00088	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SRD5A1—polycystic ovary syndrome	0.000272	0.00088	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000271	0.000873	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000264	0.000851	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000261	0.000844	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—STAR—polycystic ovary syndrome	0.00026	0.000839	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000259	0.000836	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000259	0.000836	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000256	0.000825	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00025	0.000808	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000249	0.000805	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—polycystic ovary syndrome	0.000249	0.000805	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000249	0.000803	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000246	0.000795	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000244	0.000786	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000242	0.000782	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00024	0.000776	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00024	0.000775	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000235	0.000759	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—polycystic ovary syndrome	0.000234	0.000755	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000234	0.000755	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMMR—polycystic ovary syndrome	0.000232	0.000748	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000229	0.000738	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FST—polycystic ovary syndrome	0.000228	0.000736	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000227	0.000732	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000225	0.000727	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000224	0.000724	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000223	0.000719	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000222	0.000718	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HSD3B1—polycystic ovary syndrome	0.000221	0.000714	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000219	0.000709	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000218	0.000704	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NMNAT3—polycystic ovary syndrome	0.000218	0.000703	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000217	0.000702	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—VEGFA—polycystic ovary syndrome	0.000216	0.000697	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000211	0.00068	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000211	0.00068	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00021	0.000678	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000208	0.000673	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000208	0.000672	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000206	0.000664	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000205	0.000662	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000203	0.000655	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LHB—polycystic ovary syndrome	0.000202	0.000651	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FST—polycystic ovary syndrome	0.0002	0.000645	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SUOX—polycystic ovary syndrome	0.000199	0.000643	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPCAT2—polycystic ovary syndrome	0.000199	0.000643	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000199	0.000642	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000199	0.000641	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000197	0.000637	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HSD3B2—polycystic ovary syndrome	0.000197	0.000636	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000195	0.000631	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000195	0.00063	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000194	0.000626	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKR1C1—polycystic ovary syndrome	0.000191	0.000616	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000191	0.000616	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000191	0.000615	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000189	0.000612	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000185	0.000599	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ISYNA1—polycystic ovary syndrome	0.000185	0.000598	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000185	0.000596	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000184	0.000595	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000184	0.000595	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000183	0.00059	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000181	0.000584	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.00018	0.000582	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000178	0.000576	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000178	0.000575	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SULT2A1—polycystic ovary syndrome	0.000176	0.000567	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000174	0.000563	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000173	0.000559	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000171	0.000553	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000171	0.000551	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—RRM2—polycystic ovary syndrome	0.00017	0.000549	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00017	0.000549	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FST—polycystic ovary syndrome	0.000169	0.000545	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000168	0.000542	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000167	0.00054	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000167	0.000539	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000165	0.000532	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—YAP1—polycystic ovary syndrome	0.000164	0.000529	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—polycystic ovary syndrome	0.000163	0.000527	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000162	0.000523	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000161	0.00052	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.00016	0.000515	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000159	0.000512	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000158	0.00051	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NAMPT—polycystic ovary syndrome	0.000157	0.000509	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TEAD2—polycystic ovary syndrome	0.000157	0.000508	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKR1C2—polycystic ovary syndrome	0.000157	0.000508	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000156	0.000505	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000156	0.000504	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000156	0.000503	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP11A1—polycystic ovary syndrome	0.000156	0.000502	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000154	0.000499	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000152	0.000492	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INSR—polycystic ovary syndrome	0.00015	0.000483	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000147	0.000476	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKR1C3—polycystic ovary syndrome	0.000147	0.000474	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000147	0.000474	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000147	0.000474	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000145	0.000468	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP17A1—polycystic ovary syndrome	0.000145	0.000467	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000144	0.000464	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—polycystic ovary syndrome	0.000142	0.00046	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000142	0.000459	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000141	0.000457	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000141	0.000456	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	0.00014	0.000453	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.00014	0.000452	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.00014	0.000452	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000138	0.000447	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000137	0.000441	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000136	0.000439	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000134	0.000433	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000132	0.000427	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PNPLA2—polycystic ovary syndrome	0.000132	0.000426	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	0.00013	0.000421	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000129	0.000417	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000129	0.000416	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000129	0.000416	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000128	0.000415	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000128	0.000414	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000126	0.000408	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TH—polycystic ovary syndrome	0.000125	0.000404	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SRD5A1—polycystic ovary syndrome	0.000125	0.000404	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000124	0.0004	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000123	0.000399	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000123	0.000397	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC2A4—polycystic ovary syndrome	0.000122	0.000393	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000122	0.000392	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.00012	0.000388	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.00012	0.000387	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—STAR—polycystic ovary syndrome	0.000119	0.000385	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000119	0.000385	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	0.000119	0.000385	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000118	0.000382	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000117	0.000378	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP19A1—polycystic ovary syndrome	0.000114	0.000369	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000113	0.000366	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000113	0.000364	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000113	0.000364	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000112	0.000363	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000109	0.000351	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000109	0.000351	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000108	0.00035	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000107	0.000347	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—polycystic ovary syndrome	0.000107	0.000344	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000107	0.000344	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMMR—polycystic ovary syndrome	0.000106	0.000343	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000105	0.00034	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000105	0.000338	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000104	0.000335	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GNAS—polycystic ovary syndrome	0.000102	0.00033	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSD3B1—polycystic ovary syndrome	0.000101	0.000327	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000101	0.000327	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000101	0.000325	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	0.0001	0.000323	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GNAS—polycystic ovary syndrome	9.88e-05	0.000319	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NCOR1—polycystic ovary syndrome	9.73e-05	0.000314	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NGFR—polycystic ovary syndrome	9.58e-05	0.000309	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—POMC—polycystic ovary syndrome	9.52e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRL—polycystic ovary syndrome	9.49e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.41e-05	0.000304	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LHB—polycystic ovary syndrome	9.25e-05	0.000299	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NRG1—polycystic ovary syndrome	9.24e-05	0.000298	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A1—polycystic ovary syndrome	9.22e-05	0.000298	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT2—polycystic ovary syndrome	9.15e-05	0.000295	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	9.04e-05	0.000292	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	9.03e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB2—polycystic ovary syndrome	9.01e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—polycystic ovary syndrome	8.83e-05	0.000285	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	8.75e-05	0.000283	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—polycystic ovary syndrome	8.6e-05	0.000278	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GNAS—polycystic ovary syndrome	8.35e-05	0.00027	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	8.05e-05	0.00026	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	7.96e-05	0.000257	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS2—polycystic ovary syndrome	7.91e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	7.88e-05	0.000254	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	7.81e-05	0.000252	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	7.8e-05	0.000252	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—polycystic ovary syndrome	7.74e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—POMC—polycystic ovary syndrome	7.59e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INS—polycystic ovary syndrome	7.55e-05	0.000244	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	7.52e-05	0.000243	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	7.3e-05	0.000236	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	7.29e-05	0.000235	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	7.22e-05	0.000233	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	7.13e-05	0.00023	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—polycystic ovary syndrome	6.97e-05	0.000225	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.93e-05	0.000224	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS1—polycystic ovary syndrome	6.91e-05	0.000223	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—POMC—polycystic ovary syndrome	6.88e-05	0.000222	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—INS—polycystic ovary syndrome	6.84e-05	0.000221	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	6.74e-05	0.000218	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	6.69e-05	0.000216	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—POMC—polycystic ovary syndrome	6.65e-05	0.000215	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	6.63e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INS—polycystic ovary syndrome	6.62e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—polycystic ovary syndrome	6.55e-05	0.000211	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—polycystic ovary syndrome	6.4e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT2—polycystic ovary syndrome	6.4e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.08e-05	0.000196	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	5.84e-05	0.000189	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TH—polycystic ovary syndrome	5.74e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—POMC—polycystic ovary syndrome	5.62e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INS—polycystic ovary syndrome	5.59e-05	0.000181	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	5.58e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	5.58e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	5.41e-05	0.000175	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	5.4e-05	0.000175	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	5.25e-05	0.000169	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.14e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.89e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.77e-05	0.000154	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	4.69e-05	0.000151	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	4.46e-05	0.000144	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	4.23e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.18e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	4.14e-05	0.000134	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.94e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.53e-05	0.000114	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—polycystic ovary syndrome	3.3e-05	0.000106	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	3.2e-05	0.000103	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—POMC—polycystic ovary syndrome	3.15e-05	0.000102	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—INS—polycystic ovary syndrome	3.14e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.89e-05	9.34e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—polycystic ovary syndrome	2.44e-05	7.89e-05	CbGpPWpGaD
